$2.18
3.10% today
Nasdaq, Aug 12, 07:41 pm CET
ISIN
CA27966L1085
Symbol
EDSA

Edesa Biotech Inc Stock price

$2.11
+0.02 0.96% 1M
+0.25 13.40% 6M
+0.43 25.60% YTD
-2.50 54.23% 1Y
-12.10 85.15% 3Y
-55.15 96.32% 5Y
-1,917.12 99.89% 10Y
-587.95 99.64% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.01 0.47%
ISIN
CA27966L1085
Symbol
EDSA
Industry

Key metrics

Basic
Market capitalization
$14.8m
Enterprise Value
$930.0k
Net debt
positive
Cash
$13.9m
Shares outstanding
7.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.0
Financial Health
Equity Ratio
51.9%
Return on Equity
-311.5%
ROCE
-41.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-6.3m | -
EBIT
$-6.5m | $-7.2m
Net Income
$-5.8m | $-10.0m
Free Cash Flow
$-5.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
23.9% | -
EBIT
23.9% | -3.3%
Net Income
19.4% | -62.4%
Free Cash Flow
9.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.1
FCF per Share
$-0.8
Short interest
0.3%
Employees
16
Rev per Employee
$0.0
Show more

Is Edesa Biotech Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Edesa Biotech Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Edesa Biotech Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Edesa Biotech Inc forecast:

Buy
88%
Hold
13%

Financial data from Edesa Biotech Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.97 3.97
15% 15%
-
- Research and Development Expense 2.51 2.51
35% 35%
-
-6.31 -6.31
24% 24%
-
- Depreciation and Amortization 0.16 0.16
27% 27%
-
EBIT (Operating Income) EBIT -6.47 -6.47
24% 24%
-
Net Profit -5.84 -5.84
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about Edesa Biotech Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edesa Biotech Inc Stock News

Negative
The Motley Fool
4 days ago
Edesa Biotech Posts Narrower Loss in Q3
Neutral
GlobeNewsWire
4 days ago
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.
Neutral
GlobeNewsWire
3 months ago
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2025 and provided an update on its business. During the quarter, the company completed a $15 million equity financin...
More Edesa Biotech Inc News

Company Profile

Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company product candidate, EB01, is a sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded in 2007 and is headquartered in Markham, Canada.

Head office Canada
CEO Pardeep Nijhawan
Employees 16
Founded 2007
Website www.edesabiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today